DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Final phase 3 data from the ROSELLA trial showed that adding relacorilant to nab‑paclitaxel significantly improved overall survival in patients with platinum‑resistant ovarian cancer, supporting the regimen’s recent FDA approval and inclusion in clinical guidelines.
Key Clinical Considerations
- The relacorilant plus nab‑paclitaxel combination produced a clinically meaningful overall survival benefit compared with nab‑paclitaxel alone in a heavily pretreated population.
- Survival benefits were consistent across key subgroups, including patients with high‑risk disease characteristics, without requiring biomarker selection.
- The safety profile was manageable, with no fatal adverse events related to relacorilant and no reported cases of adrenal insufficiency.
Clinical Practice Impact
- Establishes a new treatment option for patients with platinum‑resistant ovarian cancer, an area with limited effective therapies.
- Supports use of the combination regimen without biomarker testing, simplifying patient selection in clinical practice.
- Reinforces guideline‑aligned adoption following FDA approval and inclusion in National Comprehensive Cancer Network recommendations.
More in Ovarian Cancer
